Injections are a viable option for sufferers of knee osteoarthritis

Osteoarthritis (OA) is the most common form of arthritis that affects nearly one in six Canadians.

It is a debilitating condition that causes chronic pain and loss of function due to the breakdown of cartilage – the flexible connective tissue found in joints – with the knee being commonly affected.

Research shows that prior trauma such as injury to the anterior cruciate ligament (ACL) in the knee, can increase a person’s chance of developing OA of the knee later in life.

While there is no cure for OA, there are several treatments that include arthroscopic surgery. The Arthroscopy Association of Canada (ACC) recently recommended that prior to undergoing surgery, non-operative treatments should be trialed.

Injections into the knee joint, such as corticosteroids, hyaluronic acid (HA), platelet-rich plasma (PRP) and cellular-based therapies (BMAC), are some of the non-surgical treatments available to OA sufferers in Canada, but not all of these have equally weighted scientific evidence to back up their use.

A recent publication from the AAC, that includes Banff Sport Medicine Foundation researchers and Orthopaedic Surgeons, Drs Michaela Kopka and Laurie Hiemstra, made several recommendations on which type of injections should be used for the treatment of OA based on current evidence.

Corticosteroids are a type of steroid hormone that are used to routinely treat inflammation. By reviewing the available scientific evidence, the AAC conclude that corticosteroid injections into the knee joint can provide short-term, moderate pain relief in patients with early knee OA. The AAC also conclude that corticosteroids can restore function in the knee and offer a cost-effective treatment option.

Hyaluronic Acid (HA) is a substance that is naturally present in the human body. It plays an important role in joint lubrication and is essential to the proper functioning of the joint. HA has been approved in Canada for the treatment of mild to moderate OA of the knee since 1992. The AAC conclude that injections of a specific type of HA (a high-molecular weight type) can improve pain relief and restore knee function and might be a good option for patients with mild to moderate knee OA.

Platelet rich plasma (PRP) is another type of injection that involves taking a sample of a person’s blood and concentrating the platelets. Platelets are just one main type of cell found in the blood, with red and white blood cells being the others. The platelets are best known for their role in clotting blood, but they also contain hundreds of proteins called growth factors. These growth factors are very important in the healing of injuries. Once the platelets have been concentrated, a preparation is made for injection into the knee to help stimulate healing.

Based on current research, the AAC conclude that PRP injection “has the potential to provide improvements in pain and functional outcomes up to 1 year after the injection in patients with mild to moderate OA”. Due to the lack of consensus in research findings and the ideal PRP preparation, the AAC can’t make a conclusive recommendation on whether PRP should be used until further high-quality clinical studies (the gold standard in human research) become available.

Another type of therapy that has shown potential for the treatment of OA is Cellular-Based Therapies (BMAC). This type of therapy typically involves injecting stem cells (or early stem cells) into the knee to promote healing. While promising results have been shown in clinical trials for BMAC, it is currently not approved by Health Canada as an OA therapy. Thus, the AAC recommend that the use of BMAC be restricted to controlled clinical trials until there is enough evidence to support its use in routine clinical practice.

To learn more about OA or these types of injections, read the AAC publication here, or visit the Banff Sport Medicine Injection Information page.

Medial Patellofemoral Ligament (MPFL) Reconstruction Research Perspective

Another research perspective published in Healio on a project led by Banff Sport Medicine Orthopaedic surgeon, Dr Laurie Hiemstra, and Research Director, Sarah Kerslake!

Hiemstra, L. A., & Kerslake, S. (2019). Age at Time of Surgery but Not Sex Is Related to Outcomes After Medial Patellofemoral Ligament Reconstruction. The American Journal of Sports Medicine, 47(7), 1638–1644.

“By stratifying for pathoanatomic risk factors, this study has clarified that females do not have poorer outcomes following [medial patellofemoral ligament] MPFL reconstruction based on their sex,” Laurie Hiemstra, MD, told

“Previous research has correlated female sex with poorer outcomes after patellar stabilization surgery, however females demonstrate a greater number of pathoanatomic risk factors, which adversely influence outcomes. Likewise, individuals who dislocate at a young age are likely to have a greater number of pathoanatomic risk factors.”

Read more about this Perspective here.